加拿大努纳武特地区普及婴儿乙型肝炎病毒(HBV)疫苗接种二十年后的血清学与分子流行病学结果
结果显示,1980年后出生者HBV暴露率较1980年前出生者降低10倍(1.8% vs 19.8%,p<0.01);HBsAg阳性率在1980年前出生者为2.5%,疫苗年龄队列为0.3%;HBV总患病率降至1.2%,提示非地方性流行,但疫苗年龄队列中疫苗诱导抗体作为唯一血清学标志物的比例随年龄增长下降速度远超预期(5-19岁者<10%),需进一步调查。
要点
- 1980年后出生者HBV暴露率较1980年前出生者降低10倍(1.8% vs 19.8%,p<0.01)。
- HBsAg阳性率在1980年前出生者为2.5%,疫苗年龄队列为0.3%。
- HBV总患病率降至1.2%,提示非地方性流行;但疫苗年龄队列中疫苗诱导抗体衰减速度远超预期(5-19岁者<10%),需进一步调查。
核心结论
- 努纳武特地区实施HBV疫苗接种近二十年后,HBV患病率降至1.2%,提示非地方性流行;但感染持续存在及疫苗年龄队列中疫苗诱导免疫率低于预期,需进一步调查原因和后果。
研究设计与样本
- 检测HBV抗体、表面抗原(HBsAg)和HBV DNA,并进行分子特征分析。
主要发现
- HBV核心抗体阳性率为9.4%;1980年后出生者HBV暴露率为1.8%,1980年前出生者为19.8%,后者较前者高10倍(p<0.01)。
- HBsAg阳性主要见于1980年前出生者(2.5%),疫苗年龄队列为0.3%。
- HBV亚基因型B5(既往称B6)为最常见基因型(81.8%),提示本地获得性感染持续存在。
- 疫苗年龄队列中疫苗诱导抗体作为唯一血清学标志物常见,但随年龄增长衰减速度远超预期(5-19岁者<10%)。
- HBV总患病率降至1.2%,提示非地方性流行。
关键数值与推荐
- 1980年后出生者HBV暴露率为1.8%,1980年前出生者为19.8%(p<0.01)。
- HBsAg阳性率在1980年前出生者为2.5%,疫苗年龄队列为0.3%。
- HBV亚基因型B5占81.8%。
- 疫苗年龄队列中5-19岁者疫苗诱导抗体作为唯一血清学标志物的比例<10%。
- HBV总患病率为1.2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出,疫苗年龄队列中疫苗诱导免疫率低于预期,需进一步调查以了解原因和后果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic hepatitis B virus (HBV) infection within the Canadian Arctic is considered endemic (>2% prevalence). Within the Arctic region of Nunavut, a vaccination program targeted at newborn infants was initiated approximately 20years ago, along with interim grade school catch-up programs, with the result that individuals born after 1980 are presumed vaccinated. This study investigates the effectiveness of these programs and is the first seroepidemiological survey to determine HBV prevalence in Nunavut in the post-vaccination era. Anonymized serum specimens scheduled for destruction following medical testing were collected between April 2013 and April 2014 from individuals granting consent. Specimens were tested for HBV antibodies, surface antigen (HBsAg), and HBV DNA to perform molecular characterization. Four thousand eight hundred and two specimens (13% of the population) were collected, with a resulting median age of 29years (range 1week to 93years). The prevalence of antibody to the HBV core protein was 9.4%; however, a 10-fold decrease in the rate of HBV exposure was noted among those born after 1980 compared to those born before (1.8% vs. 19.8%, p<0.01). HBsAg positivity was primarily documented in individuals born before 1980 (2.5%), although cases still occurred among the vaccine age cohort (0.3%). HBV subgenotype B5 (previously B6) was the most prevalent genotype observed (81.8%) indicating persistence of locally acquired infection. Vaccine-based antibody as the sole serological marker was evident in the vaccine age cohort, although the rate of decay with increasing age was much greater than predicted (less than 10% in those aged 5-19years). Nearly two decades after the advent of HBV vaccination in Nunavut, HBV prevalence has decreased to 1.2%, indicating non-endemic prevalence. However, the persistence of infection and a lower than expected prevalence of vaccine-based immunity in the vaccine age cohort will require further investigation to understand the causes and consequences.
引用
- Huynh C, Minuk GY, Uhanova J, et al. Serological and molecular epidemiological outcomes after two decades of universal infant hepatitis B virus (HBV) vaccination in Nunavut, Canada. Vaccine. 2017. PMID: 28736196. doi:10.1016/j.vaccine.2017.07.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。